Nature CommunicationsCancer BiologyPeer-reviewed journal article
CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells
Dorian V. ZiegleriD, Kanishka ParashariD, Lucía C. Leal-EstebaniD, Jaime López‐AlcaláiD, Wilson CastroiD, Nadège ZanouiD, Laia Martínez-CarreresiD, Katharina HuberiD, Xavier Pascal Berney, Marı́a M. MalagóniD, Catherine Roger, Marie-Agnès BergeriD, Yves GouriouiD, Giulia Paone, Héctor Gallart‐AyalaiD, George SflomosiD, Carlos Henrique Venturi RonchiiD, Julijana IvaniševićiD, Cathrin BriskeniD, Jennifer RieussetiD, Melita B. IrvingiD, Lluís FajasiD
Abstract
The shift in the energetic demands of proliferating cells during tumorigenesis requires intense crosstalk between the cell cycle and metabolism. Beyond their role in cell proliferation, cell cycle regulators also modulate intracellular metabolism in normal tissues. However, in the context of cancer, where CDK4 is upregulated or stabilized, the metabolic role of CDK4 is barely understood. Using both genetic and pharmacological approaches, we aimed to determine the metabolic role of CDK4 in TNBC cells. Unexpectedly, deletion of CDK4 only slightly reduced triple-negative breast cancer (TNBC) cell proliferation and allowed tumor formation in vivo. Furthermore, proapoptotic stimuli failed to induce appropriate cell death in TNBC cells with CDK4 depletion or long-term CDK4/6 inhibitor treatment. Mechanistically, CDK4 enhances mitochondria-ER contact (MERC) formation, thus promoting mitochondrial fission and ER-mitochondrial calcium signaling. Phosphoproteomic analysis also revealed a role for CDK4 in regulating PKA activity at MERCs to sustain ER-mitochondrial calcium signaling. This proper CDK4-mediated mitochondrial calcium signaling is then required for metabolic flexibility of TNBC cells. Taken together, these results demonstrate that CDK4 inhibition leads to cell death resistance, inhibiting mitochondrial apoptosis and functions through attenuated MERCs formation and ER-mitochondrial calcium signaling in TNBC. Overall, this study provides new insights into the mechanisms of TNBC resistance to CDK4/6i therapy and paves the way to explore potential synergistic therapeutic targeting MERCs-associated metabolic shifts. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=158 HEIGHT=200 SRC="FIGDIR/small/613455v1_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@36f496org.highwire.dtl.DTLVardef@1f3aa1dorg.highwire.dtl.DTLVardef@258d49org.highwire.dtl.DTLVardef@15ed9a6_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: cell signaling & trafficking
- approach: experimental assay
- Citations
- 14
- FWCI
- 3.48
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CDK4 Restricts Triple-Negative Breast Cancer Cell Migration via Phosphorylation-Driven Activation of Myo9b RhoGAP Function
Kanishka Parashar, Laia Simó‐Riudalbas, … Lluis Fajas A·bioRxiv·Aug 6, 2025
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity
D. Biswas, L. Slade, … T. Pulinilkunnil·bioRxiv·May 18, 2021
- TRPML1 signaling at lysosomes-mitochondria nexus drives triple-negative breast cancer mitophagy, metabolic reprogramming and chemoresistance
Alia Kazim Rizvi Syeda, Shekoufeh Almasi, … Yassine El Hiani·bioRxiv·Sep 11, 2025
- A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer
Qiyun Deng, Mehdi Amiri, … Nahum Sonenberg·bioRxiv·Sep 16, 2026
- BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators
O. Castellanet, F. Ahmad, … F. Maina·bioRxiv·Mar 16, 2021
- On the therapeutic potential of MAPK4 in triple-negative breast cancer
F. Boudghene-Stambouli, M. Soulez, … S. Meloche·bioRxiv·Aug 24, 2022